TYRA BIOSCIENCES INC (TYRA) Stock Fundamental Analysis

NASDAQ:TYRA • US90240B1061

29.33 USD
+0.21 (+0.72%)
Last: Feb 18, 2026, 12:49 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TYRA. TYRA was compared to 521 industry peers in the Biotechnology industry. TYRA has a great financial health rating, but its profitability evaluates not so good. TYRA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year TYRA has reported negative net income.
  • In the past year TYRA has reported a negative cash flow from operations.
  • In the past 5 years TYRA always reported negative net income.
  • TYRA had a negative operating cash flow in each of the past 5 years.
TYRA Yearly Net Income VS EBIT VS OCF VS FCFTYRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • TYRA has a Return On Assets of -37.00%. This is in the better half of the industry: TYRA outperforms 60.27% of its industry peers.
  • TYRA's Return On Equity of -39.81% is fine compared to the rest of the industry. TYRA outperforms 70.63% of its industry peers.
Industry RankSector Rank
ROA -37%
ROE -39.81%
ROIC N/A
ROA(3y)-25.06%
ROA(5y)-28.43%
ROE(3y)-26.84%
ROE(5y)-31.19%
ROIC(3y)N/A
ROIC(5y)N/A
TYRA Yearly ROA, ROE, ROICTYRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

  • TYRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TYRA Yearly Profit, Operating, Gross MarginsTYRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for TYRA has been increased compared to 1 year ago.
  • Compared to 5 years ago, TYRA has more shares outstanding
  • There is no outstanding debt for TYRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TYRA Yearly Shares OutstandingTYRA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
TYRA Yearly Total Debt VS Total AssetsTYRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 41.80 indicates that TYRA is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of TYRA (41.80) is better than 95.01% of its industry peers.
  • TYRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 41.8
ROIC/WACCN/A
WACCN/A
TYRA Yearly LT Debt VS Equity VS FCFTYRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 17.71 indicates that TYRA has no problem at all paying its short term obligations.
  • TYRA's Current ratio of 17.71 is amongst the best of the industry. TYRA outperforms 94.43% of its industry peers.
  • A Quick Ratio of 17.71 indicates that TYRA has no problem at all paying its short term obligations.
  • TYRA has a better Quick ratio (17.71) than 94.43% of its industry peers.
Industry RankSector Rank
Current Ratio 17.71
Quick Ratio 17.71
TYRA Yearly Current Assets VS Current LiabilitesTYRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for TYRA have decreased strongly by -16.15% in the last year.
EPS 1Y (TTM)-16.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • TYRA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.36% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-33.92%
EPS Next 2Y-23.75%
EPS Next 3Y-16.25%
EPS Next 5Y12.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TYRA Yearly Revenue VS EstimatesTYRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
TYRA Yearly EPS VS EstimatesTYRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TYRA. In the last year negative earnings were reported.
  • Also next year TYRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TYRA Price Earnings VS Forward Price EarningsTYRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TYRA Per share dataTYRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • TYRA's earnings are expected to decrease with -16.25% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.75%
EPS Next 3Y-16.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • TYRA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TYRA BIOSCIENCES INC

NASDAQ:TYRA (2/18/2026, 12:49:47 PM)

29.33

+0.21 (+0.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)03-25
Inst Owners104.62%
Inst Owner Change-7.26%
Ins Owners2.98%
Ins Owner Change-2.87%
Market Cap1.57B
Revenue(TTM)N/A
Net Income(TTM)-111.68M
Analysts87.5
Price Target42.59 (45.21%)
Short Float %9.69%
Short Ratio7.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.16%
Min EPS beat(2)1.47%
Max EPS beat(2)12.85%
EPS beat(4)4
Avg EPS beat(4)8.12%
Min EPS beat(4)1.47%
Max EPS beat(4)12.85%
EPS beat(8)6
Avg EPS beat(8)8.92%
EPS beat(12)9
Avg EPS beat(12)7.27%
EPS beat(16)10
Avg EPS beat(16)0.94%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)28.96%
PT rev (3m)31.64%
EPS NQ rev (1m)-0.21%
EPS NQ rev (3m)-0.29%
EPS NY rev (1m)0.2%
EPS NY rev (3m)0.31%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.58
P/tB 5.58
EV/EBITDA N/A
EPS(TTM)-1.87
EYN/A
EPS(NY)-2.31
Fwd EYN/A
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.71
OCFYN/A
SpS0
BVpS5.26
TBVpS5.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -37%
ROE -39.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.06%
ROA(5y)-28.43%
ROE(3y)-26.84%
ROE(5y)-31.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.13%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.71
Quick Ratio 17.71
Altman-Z 41.8
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)177.58%
Cap/Depr(5y)324.83%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.95%
EPS Next Y-33.92%
EPS Next 2Y-23.75%
EPS Next 3Y-16.25%
EPS Next 5Y12.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.06%
EBIT Next 3Y-18.61%
EBIT Next 5YN/A
FCF growth 1Y-86.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-87.5%
OCF growth 3YN/A
OCF growth 5YN/A

TYRA BIOSCIENCES INC / TYRA FAQ

What is the fundamental rating for TYRA stock?

ChartMill assigns a fundamental rating of 3 / 10 to TYRA.


Can you provide the valuation status for TYRA BIOSCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to TYRA BIOSCIENCES INC (TYRA). This can be considered as Overvalued.


How profitable is TYRA BIOSCIENCES INC (TYRA) stock?

TYRA BIOSCIENCES INC (TYRA) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for TYRA stock?

The Earnings per Share (EPS) of TYRA BIOSCIENCES INC (TYRA) is expected to decline by -33.92% in the next year.